Global Medical Device Reprocessing Market, By Type of Medical Device

According to the new market research report “Medical Device Reprocessing Market by Product (Reprocessed Dev      ice (Catheter, Endoscope, Laparoscopic Instruments, Biopsy, Pulse Oximeter), Service), Application (Cardiology, Gastroenterology, Arthroscopy, Orthopedic, Anesthesia) - Global Forecast to 2022", published by MarketsandMarkets™, The medical device reprocessing market is expected to reach USD 1,754 Million by 2022 from an estimated USD 823.5 Million in 2017, at a CAGR of 16.3%.

Early buyers will receive 10% customization on reports @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=583

The global medical device reprocessing market is projected to reach USD 1,754.0 million by 2022 from USD 823.5 million in 2017, at a CAGR of 16.3% during the forecast period. The medical device reprocessing market is emerging and fragmented in nature with various regional and national players. In 2016, Stryker Corporation (U.S.) and Johnson & Johnson (U.S.) dominated the medical device reprocessing market and accounted for approximately 80% to 85% share of the North American medical device reprocessing market.
Stryker Corporation (U.S.) dominated the global medical device reprocessing market in 2016. The company offers a comprehensive range of standards and services for reprocessing of various medical devices used in different application areas. It offers its services and reprocessed medical devices through the Sustainability Business segment; also known as Stryker’s Sustainability Solutions (SSS). To maintain its leading position and increase its customer base in the medical device reprocessing market, the company mainly focuses on strategic partnerships with hospitals and other healthcare organizations. Currently, the company has partnered with around 3,000 hospitals in the U.S. for reprocessing of medical devices.


The report analyzes the medical device reprocessing market by product & service, type of medical device, application, and region. On the basis of product & service, the reprocessing support and services segment accounted for the largest share in 2016, owing to the increased adoption of third-party reprocessing services over in-house reprocessing services by hospitals, clinics, surgical centers, clinical pathologies, and other healthcare organizations.
Medical Device Reprocessing Market
Some of the other players competing in this market are Vanguard AG (Germany), Medline ReNewal (U.S.), Medtronic plc (Ireland), SteriPro Canada, Inc., Pioneer Medical Devices AG (Germany), Vascular Solutions, Inc. (U.S.), HYGIA Health Services, Inc. (U.S.), ReNu Medical, Inc. (U.S.), SureTek Medical (U.S.), and Centurion Medical Products Corporation (U.S.).
Location: Dundee Rd, Illinois, USA

Comments

Post a Comment

Popular posts from this blog

Key Players in the Pyrogen Testing Market Focus on Partnerships, Agreements, & Collaborations, Acquisitions, New Product launches, and Expansions

Image
The report  " Pyrogen Testing Market  by Product (Instruments, Services, Kits and Reagents), Application (Pharmaceutical & Biotechnology, Medical Devices, Other), & by Test (In Vitro, LAL, Gel Clot, Turbidimetric, Chromogenic, Rabbit) - Global Forecasts to 2021 " ,  report provides a detailed overview of the major drivers, restraints, opportunities, current market trends, and strategies impacting the global pyrogen testing market along with the estimates and forecasts of the revenue and market share analysis. Speak to Analyst @  https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=255266155 The global pyrogen testing market is valued at $462.38 million in 2014 and is expected to grow at a CAGR of 12.23%, to reach $823.14 million by 2019. Pyrogen testing is used to determine the bacterial toxins in products intended for medical or veterinary use. Rapidly growing pharmaceutical and biotechnology industries are a major growth driver for this market. Further
Read more

Non Invasive Prenatal Testing Market| Market Trends by Instruments, Consumables, Method, Application and End User

The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period. The non-invasive prenatal testing (NIPT) market is expected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016, at a CAGR of 16.4% from 2016 to 2021. The instruments segment is divided into ultrasound device, NGS systems, PCR instruments, microarrays, and other instruments. In 2016, the consumables segment accounted for the largest share of the market. The high growth in this segment is attributed to the repeated requirements of consumables as compared to instruments in NIPT. Based on application
Read more

Global Glycomics Market Players Pursue the Strategies of Product Launches, Agreements, Expansions, Acquisitions, and Collaborations

Image
The major players in this market include Agilent Technologies (U.S.), Bruker Corp. (U.S.), Danaher Corp. (U.S.), New England Biolabs (U.S.), Prozyme Inc. (U.S.), Shimadzu Corp. (Japan), Sigma-Aldrich Corp. (U.S.), Takara Bio (Japan), Thermo Fisher Scientific (U.S.), and Waters Corp. (U.S.). The glycomics market is dominated by a few major players, with the top five players accounting for a majority of the market share. The top four players for glycomics enzymes, kits, and reagents have a combined market share of about 75.2% and for glycomics instruments have a combined market share of about 76.0%. The global glycomics market is highly evolved, with multiple different product segments. An analysis of market developments between 2011 and 2014 revealed that new product launches was the most important growth strategy employed by market leaders in this period. This strategy was adopted by most players in this market, except New England Biolabs (U.S.) and Takara Bio, Inc. (Japan).
Read more